-
Innovation Ranking
NewInnovation Ranking – Richter Gedeon Nyrt
Gedeon Richter Plc (Gedeon Richter) is a pharmaceutical company that develops, manufactures and markets a wide range of drugs including original, generic, and licensed products and over the counter (OTC) medicines. The company’s product portfolio consists of medicines to treat gynecological diseases, gastrointestinal diseases, cardiovascular diseases and central nervous system disorders. Richter’s research activities focus exclusively on the development of original small molecules, recombinant biotechnology, and generic product development. It operates sales network in Hungary, Central Eastern Europe, and the...
-
Company Insights
Innovation and Patenting activity of Gedeon Richter Plc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Gedeon Richter Plc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis (Gedeon Richter Plc)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis (Gedeon Richter Plc) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (DTRMWXHS-12 + Everolimus + Pomalidomide) in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (DTRMWXHS-12 + Everolimus + Pomalidomide) in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (DTRMWXHS-12 + Everolimus + Pomalidomide) in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (DTRMWXHS-12 + Everolimus + Pomalidomide) in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (DTRMWXHS-12 + Everolimus + Pomalidomide) in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (DTRMWXHS-12 + Everolimus + Pomalidomide) in Follicular Lymphoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONCT-808 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONCT-808 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONCT-808 in B-Cell Non-Hodgkin Lymphoma Drug Details: ONCT-808 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-110 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-110 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-110 in Diffuse Large B-Cell Lymphoma Drug Details: CTX-110 (previously...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-110 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-110 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-110 in B-Cell Acute Lymphocytic Leukemia...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CTX-110 in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-110 in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-110 in B-Cell Chronic Lymphocytic Leukemia Drug Details: CTX-110 (previously...